Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies

by Mark C. Genovese, Patrick Durez, Roy Fleischmann, Yoshiya Tanaka, Daniel Furst, Hisashi Yamanaka, Elena Korneva, Igor Vasyutin, Tsutomu Takeuchi
Published 2021-07-01